OP \$165.00 5734840

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 ETAS ID: TM864465

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
KREOS CAPITAL VI (UK) LIMITED		12/27/2023	Corporation: ENGLAND AND WALES
KREOS CAPITAL 2020 OPPORTUNITY (UK) LIMITED		12/27/2023	Corporation: ENGLAND AND WALES

RECEIVING PARTY DATA

Name:	Calliditas Therapeutics AB
Street Address:	Kungsbron 1 D5
City:	Stockholm
State/Country:	SWEDEN
Postal Code:	SE-111 22
Entity Type:	Company: SWEDEN

PROPERTY NUMBERS Total: 6

Property Type	Number	Word Mark
Registration Number:	5734840	NEFECON
Serial Number:	90775339	TARPEYO TOUCHPOINTS
Serial Number:	88861008	TARPEYO
Serial Number:	88861021	VALKIGO
Serial Number:	88294772	CALLIDITAS THERAPEUTICS
Serial Number:	87732055	CALLIDITAS

CORRESPONDENCE DATA

Fax Number: 7043395800

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 7043311000

Email: damionnenobles@mvalaw.com, jansnider@mvalaw.com,

vangambrell@mvalaw.com

Correspondent Name: MOORE & VAN ALLEN PLLC
Address Line 1: 100 North Tryon Street, Suite 4700

Address Line 2: Attn: IP Department

Address Line 4: Charlotte, NORTH CAROLINA 28202

TRADEMARK REEL: 008303 FRAME: 0281

900824535

NAME OF SUBMITTER:	James Van Cleave Gambrell
SIGNATURE:	/James Van Cleave Gambrell/
DATE SIGNED:	12/28/2023

Total Attachments: 4

source=Release_Trademark_Collateral_from_KreosCapital_to_Calliditas_Executed_27-12-23#page1.tif source=Release_Trademark_Collateral_from_KreosCapital_to_Calliditas_Executed_27-12-23#page2.tif source=Release_Trademark_Collateral_from_KreosCapital_to_Calliditas_Executed_27-12-23#page3.tif source=Release_Trademark_Collateral_from_KreosCapital_to_Calliditas_Executed_27-12-23#page4.tif

RELEASE OF TRADEMARK COLLATERAL

THIS RELEASE OF TRADEMARK COLLATERAL (this "Release") is made as of December 27, 2023, and entered into by (1) KREOS CAPITAL VI (UK) LIMITED, a company incorporated in England and Wales, and KREOS CAPITAL 2020 OPPORTUNITY (UK) LIMITED, a company incorporated in England and Wales and the other lenders party to the Loan Agreement (as defined below) (collectively, the "Lenders"), the secured parties under the Security Agreement referred to below, in favor of (2) CALLIDITAS THERAPEUTICS AB, a company incorporated in Sweden (the "Grantor").

WITNESSETH:

WHEREAS, a certain Agreement for the Provision of Loan Facilities, dated as of July 15, 2021 (as amended, restated, supplemented or otherwise modified from time to time, the "Loan Agreement"), was executed by and among (a) Grantor, a company incorporated in Sweden, (b) each of the entities party thereto from time to time as a guarantor, and (c) the Lenders.

WHEREAS, Grantor executed that certain Intellectual Property Security Agreement, dated as of July 16, 2021 (the "Security Agreement"), pursuant to which Grantor granted a security interest to the Lenders in certain trademarks, trademark applications and other intellectual property of the Grantor; and

WHEREAS, a Grant of Security Interest – Trademarks executed by Grantor on July 16, 2021 ("<u>Grant of Security Interest – Trademarks</u>") was executed in connection with said Security Agreement and was recorded with the United States Patent and Trademark Office ("<u>USPTO</u>") on July 21, 2021 at Reel 007361 Frame 0365; and

WHEREAS, the Lenders have agreed to release their security interests in the trademarks and trademark applications identified on <u>Exhibit A</u> attached hereto and made a part hereof (the "Released Trademarks").

NOW, THEREFORE, in consideration of the promises and other good and valuable consideration, receipt of which is hereby acknowledged, the Lenders and Grantor agree as follows:

- 1. <u>Defined Terms</u>. All capitalized terms used herein but not otherwise defined herein have the meanings given to them in the Grant of Security Interest Trademarks, the Security Agreement, or the Loan Agreement.
- 2. Termination and Release. The Lenders hereby:
 - a. terminate, cancel, discharge, and release any and all security interest in and lien on all right, title, and interest of Grantor in and to the Released Trademarks, and the entire goodwill of the business of the Grantor connected with and symbolized by such Released Trademarks, and all proceeds thereof (the "Trademark Collateral"), and reconvey to the persons legally entitled thereto all of the Lenders' right, title and interest in and to the Trademark Collateral, all without warranty or representation of any kind; and

b. authorize the recordation of this Release with the USPTO and other appropriate government authorities or entities at Grantor's expense and discretion.

IN WITNESS WHEREOF, the Lenders have caused this Release to be duly executed on the date first above written.

KREOS CAPITAL VI (UK) LIMITED

By: _	4ar
Name:	Aris Constantinides
Title:	Director

KREOS CAPITAL 2020 OPPORTUNITY (UK) LIMITED

By: Acc. Name: Aris Constantinides Title: Director
ACKNOWLEDGEMENT BY GRANTOR
CALLIDITAS THERAPEUTICS AB

Name: Title:

b. authorize the recordation of this Release with the USPTO and other appropriate government authorities or entities at Grantor's expense and discretion.

IN WITNESS WHEREOF, the Lenders have caused this Release to be duly executed on the date first above written.

4126-9401-4285.3

EXHIBIT A

TRADEMARKS AND TRADEMARK APPLICATIONS

<u>Description</u>	Registration Number	Registration <u>Date</u>
NEFECON	Reg. No. 5734840	2019-04-23
Description	Application Number	Application Date
TARPEYO TOUCHPOINTS	App. No. 90775339	2021-06-15
TARPEYO	App. No. 88861008	2020-04-06
VALKIGO	App. No. 88861021	2020-04-06
CALLIDITAS THERAPEUTICS	App. No. 88294772	2019-02-08
CALLIDITAS	App. No. 87732055	2017-12-22

4126-9401-4285.3

RECORDED: 12/28/2023